Rhythm Pharmaceuticals (RYTM)
86.40
-1.21 (1.38%)
Upcoming Events
Latest Headlines
Rhythm Pharmaceuticals (RYTM) Reiterated at Market Outperform by Citizens
June 3, 2026 4:43 AM - StreetInsider
Form DEFA14A RHYTHM PHARMACEUTICALS,
May 29, 2026 4:10 PM - SEC Filing
Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026
May 29, 2026 8:00 AM - StreetInsider
Rhythm Pharmaceuticals Announces Publication of New Bardet-Biedl Syndrome Diagnostic Algorithm in the American Journal of Medical Genetics
May 28, 2026 8:00 AM - Globe NewsWire
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
May 26, 2026 8:00 AM - StreetInsider
Form 4 RHYTHM PHARMACEUTICALS, For: May 18 Filed by: Smith Hunter C
May 20, 2026 4:16 PM - SEC Filing
Form 4 RHYTHM PHARMACEUTICALS, For: May 15 Filed by: German Christopher Paul
May 19, 2026 4:16 PM - SEC Filing
Form SCHEDULE 13G/A RHYTHM PHARMACEUTICALS, Filed by: PERCEPTIVE ADVISORS LLC
May 15, 2026 4:00 PM - SEC Filing
Rhythm Pharmaceuticals Announces New Data Presentations at the 2026 European Congress of Endocrinology
May 12, 2026 8:00 AM - Globe NewsWire
Rhythm Pharmaceuticals (RYTM) PT Raised to $143 at Canaccord
May 7, 2026 6:39 AM - StreetInsider
Rhythm Pharmaceuticals (RYTM) PT Raised to $144 at Wells Fargo
May 6, 2026 8:43 AM - StreetInsider
Rhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare Conference
May 6, 2026 8:00 AM - Globe NewsWire
Rhythm Pharmaceuticals (RYTM) PT Raised to $137 at RBC Capital
May 6, 2026 6:40 AM - StreetInsider
Form S-8 RHYTHM PHARMACEUTICALS,
May 5, 2026 4:29 PM - SEC Filing
Form DEFA14A RHYTHM PHARMACEUTICALS,
May 5, 2026 4:20 PM - SEC Filing
Form 10-Q RHYTHM PHARMACEUTICALS, For: Mar 31
May 5, 2026 4:16 PM - SEC Filing
Rhythm Pharmaceuticals (RYTM) PT Raised to $133 at Stifel
May 5, 2026 10:44 AM - StreetInsider
Form 8-K RHYTHM PHARMACEUTICALS, For: May 05
May 5, 2026 7:48 AM - SEC Filing
Rhythm Pharmaceuticals (RYTM) Reports In-Line Q1 EPS, provides guidance
May 5, 2026 7:10 AM - StreetInsider
Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update
May 5, 2026 7:00 AM - Globe NewsWire
Rhythm Pharmaceuticals Announces New Data Presentations in Acquired Hypothalamic Obesity at Pediatric Endocrine Society
May 4, 2026 8:00 AM - StreetInsider
Rhythm Pharmaceuticals gets EU approval for obesity drug IMCIVREE
May 1, 2026 6:55 AM - StreetInsider
Rhythm Pharmaceuticals Announces IMCIVREE® (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothal
May 1, 2026 6:55 AM - Globe NewsWire
Form SCHEDULE 13G RHYTHM PHARMACEUTICALS, Filed by: VANGUARD CAPITAL MANAGEMENT LLC
April 30, 2026 12:56 PM - SEC Filing
Form ARS RHYTHM PHARMACEUTICALS, For: Dec 31
April 29, 2026 4:14 PM - SEC Filing
Form DEF 14A RHYTHM PHARMACEUTICALS, For: Jun 24
April 29, 2026 4:12 PM - SEC Filing
These are the best biotech stocks to own in 2026: BofA
April 19, 2026 10:00 AM - StreetInsider
Rhythm Pharmaceuticals to Report First Quarter 2026 Financial Results on Tuesday, May 5, 2026
April 9, 2026 8:00 AM - Globe NewsWire
Rhythm Pharmaceuticals (RYTM) PT Raised to $136 at RBC Capital
April 7, 2026 9:05 AM - StreetInsider
Form 4 RHYTHM PHARMACEUTICALS, For: Apr 01 Filed by: Mazabraud Yann
April 3, 2026 5:36 PM - SEC Filing
Form 4 RHYTHM PHARMACEUTICALS, For: Apr 01 Filed by: Popovits Kimberly J
April 3, 2026 5:36 PM - SEC Filing
Form 3 RHYTHM PHARMACEUTICALS, For: Apr 01 Filed by: Popovits Kimberly J
April 3, 2026 5:35 PM - SEC Filing
Form 8-K RHYTHM PHARMACEUTICALS, For: Apr 01
April 3, 2026 3:07 PM - SEC Filing
Rhythm Pharmaceuticals appoints Kim Popovits to board
April 3, 2026 9:00 AM - StreetInsider
Rhythm Pharmaceuticals Announces Changes to Board of Directors
April 3, 2026 9:00 AM - StreetInsider
Form SCHEDULE 13G/A RHYTHM PHARMACEUTICALS, Filed by: VANGUARD GROUP INC
March 27, 2026 11:33 AM - SEC Filing
Form 8-K RHYTHM PHARMACEUTICALS, For: Mar 26
March 26, 2026 4:07 PM - SEC Filing
Leerink Partners on Rhythm Pharmaceuticals (RYTM): CHMP's positive opinion, language shows potential for broad EU labeling
March 26, 2026 2:50 PM - StreetInsider
Rhythm Pharmaceuticals gets European panel backing for obesity drug
March 26, 2026 9:02 AM - StreetInsider
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalam
March 26, 2026 9:02 AM - StreetInsider
TD Cowen: 'Rhythm Pharmaceuticals (RYTM) is a top smid biotech pick'
March 24, 2026 8:35 AM - StreetInsider
Rhythm Pharmaceuticals (RYTM) PT Raised to $105 at H.C. Wainwright
March 23, 2026 6:43 AM - StreetInsider
PANTHERx selected as exclusive U.S. pharmacy for IMCIVREE expansion
March 20, 2026 1:00 PM - StreetInsider
PANTHERx® Rare Selected by Rhythm Pharmaceuticals Inc. as the Exclusive U.S. Specialty Pharmacy for the Expanded Indication for IMCIVREE® (setmelanotide)
March 20, 2026 12:59 PM - PR NewsWire
Form 8-K RHYTHM PHARMACEUTICALS, For: Mar 19
March 20, 2026 9:26 AM - SEC Filing
Rhythm Pharmaceuticals receives FDA approval for expanded IMCIVREE indication
March 19, 2026 6:30 PM - StreetInsider
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
March 19, 2026 6:30 PM - StreetInsider
RBC Capital on Biopharma: 'M&A Discussion, Whether Accurate Or Not, Can Drive Returns'
March 18, 2026 9:21 AM - StreetInsider
Rhythm Pharmaceuticals (RYTM) PT Lowered to $100 at H.C. Wainwright
March 18, 2026 7:16 AM - StreetInsider
Rhythm Pharmaceuticals (RYTM) PT Lowered to $130 at RBC Capital
March 17, 2026 8:13 AM - StreetInsider
Rhythm Pharmaceuticals (RYTM) PT Lowered to $136 at Morgan Stanley
March 17, 2026 8:06 AM - StreetInsider
Rhythm Pharmaceuticals (RYTM) PT Lowered to $130 at Needham
March 17, 2026 7:06 AM - StreetInsider
Rhythm Pharmaceuticals (RYTM) PT Lowered to $131 at Citi
March 17, 2026 6:09 AM - StreetInsider
Rhythm Pharmaceuticals (RYTM) PT Lowered to $152 at Citizens on 'Disappointing' Phase 3 EMANATE Trial
March 17, 2026 5:22 AM - StreetInsider
Stifel says Buy rated on Rhythm Pharmaceuticals (RYTM) despite EMANATE failure
March 16, 2026 6:00 PM - StreetInsider
Form 8-K RHYTHM PHARMACEUTICALS, For: Mar 16
March 16, 2026 4:31 PM - SEC Filing
Form 4 RHYTHM PHARMACEUTICALS, For: Mar 12 Filed by: Mathers Edward T
March 16, 2026 4:12 PM - SEC Filing
Rhythm Pharmaceuticals EMANATE trial fails to meet primary endpoints
March 16, 2026 4:01 PM - StreetInsider
Rhythm Pharmaceuticals Announces Topline Results from Phase 3 EMANATE Trial
March 16, 2026 4:01 PM - StreetInsider
Rhythm Pharmaceuticals (RYTM) PT Raised to $143 at Wells Fargo
March 12, 2026 5:56 AM - StreetInsider
Full Article List
